Would you risk your hearing to save your eyesight? For many patients with Thyroid Eye Disease (TED), that’s not a hypothetical dilemma—it’s the real-world tradeoff they’re asked to consider.
Teprotumumab, marketed as Tepezza, was the first FDA-approved treatment for TED and has shown dramatic improvements in eye bulging, double vision, and quality of life. But for all its groundbreaking success, this drug doesn’t come without serious baggage. Side effects range from mildly annoying to potentially life-altering, making informed decision-making essential.
This isn’t your average prescription where you ignore the insert and pop a pill. Teprotumumab is delivered through IV infusion every three weeks for eight doses, and the impact goes far beyond the infusion chair. Some patients walk away with their vision protected and lives changed; others report permanent hearing damage or worsening blood sugar levels.
Before stepping into Teprotumumab treatment, patients and providers alike need a full picture of the risks, because the stakes are high and the science is still evolving.
Commonly Reported Side Effects of Teprotumumab
Teprotumumab infusions common side effects aren’t infrequent. According to clinical trials and real-world observational studies, most patients experience at least one adverse event. The most frequently reported issues include:
- Muscle cramps
- Nausea
- Hair loss (alopecia)
- Fatigue
- Diarrhea
- Dry skin
In the pivotal OPTIC trial, nearly 90% of participants reported side effects, though most were mild to moderate in severity and often resolved post-treatment. Muscle spasms and GI-related symptoms tend to show up early in the infusion schedule and are usually managed with supportive care like hydration and electrolyte balancing.
Still, mild doesn’t mean harmless, especially when treatment spans several months. Cumulative effects can wear patients down, particularly when they overlap with the physical and emotional exhaustion already caused by TED itself.
Hearing Loss and Other Serious Adverse Events
Hearing issues have become one of the most talked-about adverse events of teprotumumab in TED patients, and for good reason. While the medication was celebrated for its impact on Thyroid Eye Disease, many patients didn’t expect that their ears would be affected. Some report hearing loss that lingers long after treatment, while others experience strange sensations like hearing their voice echo loudly in their head or feeling pressure that doesn’t ease up.
The most eye-opening findings came from a 2023 study, which showed that hearing-related events might affect far more patients than initially thought. Not only were ear-related symptoms common, but for some, the changes were long-lasting or even permanent. This shift in understanding has raised new concerns and prompted further studies to understand what’s going on.
In a smaller group of patients, teprotumumab has also been linked to flare-ups of conditions like inflammatory bowel disease. It can also cause blood sugar spikes, especially in people with pre-existing diabetes. These aren’t everyday side effects, but they’re significant enough that doctors now screen much more carefully before starting treatment.
Risk Factors That May Increase Side Effect Severity
Teprotumumab doesn’t affect everyone the same way. Some patients move through treatment with only minor issues, while others hit unexpected roadblocks early on. The difference often comes down to individual risk factors that can make side effects more likely or more severe.
People with diabetes or insulin resistance are often more vulnerable to blood sugar spikes while on this medication. If you’ve had any hearing trouble in the past—whether it’s ear infections, hearing aids, or even just sensitivity—you’re more likely to notice changes during treatment.
And for those with conditions like Crohn’s or ulcerative colitis, there’s a slight but real chance that symptoms could worsen.
We don’t yet have a perfect system for predicting who will tolerate teprotumumab well. Genetics, metabolism, and overall health all play a role. That’s why upfront testing, detailed health history reviews, and regular follow-ups aren’t just helpful; they’re essential.
Monitoring and Managing Side Effects During Treatment
Once treatment begins, staying on top of potential side effects becomes part of the routine. Teprotumumab is powerful, and that means it demands close attention. Audiologists usually recommend a hearing test before the first infusion and follow-up testing as treatment continues.
That way, if something changes, it can be caught early.
Blood sugar should also be monitored, especially for patients who are diabetic or borderline. Some providers ask for readings before and after each infusion to spot problems before they snowball. If patients start feeling overly tired, crampy, or nauseous, hydration and simple electrolyte fixes often help. For anything that doesn’t improve quickly, medical teams step in with targeted care.
When side effects are mild, teprotumumab treatment usually continues without changes. But if symptoms worsen or become disruptive, doctors may pause infusions, adjust doses, or stop treatment altogether for that patient. The goal is always to get the benefits of teprotumumab without letting the risks take over.
Balancing Benefit vs. Risk in Active Thyroid Eye Disease
Thyroid Eye Disease can be aggressive and deeply disruptive. For some, it affects vision, causes severe eye bulging, or leads to constant discomfort that interferes with daily life. In those cases, teprotumumab may be the only real option short of surgery, offering a way to regain comfort, restore appearance, and possibly avoid long-term vision damage.
But not every thyroid eye disease case is severe. When symptoms are moderate or stable, the decision becomes less clear-cut. Is the chance to shrink eye bulging worth the increased possibility of hearing loss? Will a few months of treatment result in a better long-term quality of life, or trade one issue for another?
These are tough questions without easy answers. What matters most is weighing your personal health picture, lifestyle, and comfort level with risk. The same treatment can be life-changing for one person and unnecessarily risky for another. That’s why thoughtful, individualized care is so critical.
Ongoing Studies on Long-Term Safety Profiles
Teprotumumab was approved in 2020, which means the long-term story is still unfolding. While early results were promising, and the medication has helped thousands of people, researchers are still learning how it behaves in the body over time.
There are multiple studies underway to track side effects that show up later, linger longer, or evolve after thyroid eye disease treatment ends. Special attention is being paid to hearing-related outcomes, especially now that more patients have reported long-term or permanent issues. Researchers are also exploring ways to reduce those risks, including potential dose changes or additional therapies to protect the ears.
As new data comes in, treatment guidelines may shift. For now, the best approach is to stay informed, stay monitored, and make decisions based on the most current evidence available.
English 
Spanish